- Exhibit & Support
- Travel & Hotels
You have to weigh the advantages of new and emerging products. For insulin, these include U300 insulin, U500 insulin, and insulin degludec; while these agents expand therapeutic options, they also complicate decisions for many pharmacists. Now, pharmacists must consider not only administration, storage, and counseling, but also access—because cost may be a barrier. During this session, experts will use patient cases to demonstrate the appropriate use of various insulin therapies and describe strategies that support patient access.
At the completion of this knowledge-based activity, participants will be able to:
Supported by an independent educational grant from Novo Nordisk.